Novavax | NVAX - Interest Expense On Debt


Novavax reported $5.82M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Adma Biologics USD 1.63M 54K Dec/2025
Agenus USD 16.02M 2.85M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Cassava Sciences USD 108.37M 396.06M Mar/2026
Geron USD 7.15M 150K Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
MannKind USD 12.43M 1.44M Mar/2026
Merck USD 479M 67M Mar/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 11.49B 36B Mar/2026
Novartis USD 281M 8M Sep/2025
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 671M 40M Mar/2026
Sanofi EUR 178M 203M Mar/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
TG Therapeutics USD 7.67M 1.13M Mar/2026